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INTRODUCTION 
ANTIMICROBIALS: 
    Antimicrobial chemotherapy has been an important medical treatment.  Since, the first 
investigations of antibacterial dyes by Ehrlich in the beginning of the twentieth century, however, by 
the late 1940’s bacteria resistant to antimicrobials were recognized as a serious problem in clinical 
environments such as hospitals and care facilities. 
   Bacterial resistant forces the research communities to develop method of altering 
structures of antimicrobial compound to avoid their inactivation yet structural modification alone are 
not enough to avert bacterial resistance. 
  The increasing use of household antibacterial products and agricultural antibacterial 
fosters resistance to drug specific for human therapy and may have huge consequences for 
particularly children and elderly people.(1) 
                      Bacterial cell walls are unique structures that serve as ideal targets for antimicrobial 
drugs.  The agents that interfere with bacterial cell wall biosynthesis or cell integrity have been used 
therapeutically with high efficacy and good safety.  Because there is no comparable structure in 
mammalians bacterial cell wall inhibitors can exhibits high target specificity with the side effect 
profiles that are target related, unlike some other classes of antibiotics.  In addition, cell wall active 
agents are frequently bactericidal in their actions, providing the opportunity for complete bacterial 
clearance in serious infections.(2)   
  The multidrug resistant of bacterial and fungal strains of clinically important 
pathogens fetches the interest of scientist to develop newer broad spectrum antimicrobial agents.(3)  
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The less availability and high cost and greater side effects of new generation antibiotics necessiciates 
looking for the substances from alternative medicines which claimed antimicrobial activity have been 
reported in literature.(4-6) 
ANTI-TUBERCULOSIS: 
  Tuberculosis (TB) is an infectious disease, caused by the bacterium called 
Mycobacterium tuberculosis which is slow growing bacteria.  It was first isolated by Robert Koch in 
1882 (Rathore madhu et al., 2012).(7)  Tuberculosis remains a global public health problem especially 
in developing countries.  It is an air born communicable disease caused by transmission of 
aerosolized droplets of Mycobacterium tuberculosis, affecting all the organs in the body that rich in 
blood and oxygen, the lungs being most commonly affected. 
  Despite the availability of effective anti-tuberculosis chemotherapy for over 60 years,   
the incidence of tuberculosis continues to persist.  The World Health Organization (WHO) declared 
tuberculosis as global emergence in 1993. 
  In 2010, there were an estimated 8.8 million incident cases of tuberculosis globally, 
equivalent to 128 cases per 1, 00,000 population.  Many of the reported number of cases in 2010 
occurred in Asia (59%) and Africa (26%).  The five countries with the largest number of tuberculosis 
cases during 2010 were in India (2.0 million – 2.5 million), china (0.9 million – 1.2 million), South 
Africa (0.40 million – 0.59 million), Indonesia (0.37 million – 0.54 million) and Pakistan (0.33 
million – 0.48 million).  India alone accounted for an estimated one quarter (26%) of all tuberculosis 
cases worldwide, and China and India together accounted for 38% (WHO Report 2011).(8) 
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  World Health Organization and National TB Programme recommend four drugs 
(Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) for 2 months in initial phase and then two 
drugs (Rifampicin and Isoniazid) for 4 months as continuation phase via DOTS (Directly Observed 
Therapy Short course) for current treatment of tuberculosis (TB).  The regimen must be administered 
for at least 6 months to be fully effective in humans.(9,10). 
  A number of antimicrobial agents already exist but the search for new drugs continues 
since the target organism evolves into new genetic variant.  The chemical efficacy of many existing 
anti-biotic is being threatened by the emergence of multidrug resistance pathogens.  The increasing 
incidence of MDR (Multi Drug Resistance) and XDR (Extreme Drug Resistance)-Tuberculosis 
worldwide highlights the urgent need to search for anti-tuberculosis compound/drug, to increasing the 
probability of finding appropriate drug.  The present study was carried out to investigate and estimate 
the new compound which have been used to treat respiratory infections for its anti-tubercular activity 
by using H37Rv standard strain and resistant isolates.(11) 
 The original antibiotics were derived from fungal source.  There can be referred to as natural 
antibiotics. 
 Organisms develop resistance faster to the natural antimicrobials because they have been pre-
exposed to these compounds in nature.  Natural antibiotics are often more toxic than synthetic 
antibiotics. 
 Semi synthetic drug were developed to decrease the toxicity and increase the effectiveness. 
 Synthetic drug have an advantage that the bacteria are not exposed to the compound until they 
are released.  They are also designed to have even greater effectiveness and less toxicity. 
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 5-Nitro 2-Thiophene carboxaldehyde is a synthetic compound which is used as intermediate 
compound to synthesis new derivatives of many novel compounds having excellent antimicrobial, 
antitubercular, anti-inflammatory, anticancer, analgesic, antihistaminic, antiviral, antipsychotic, 
diuretic activity.  In this study antimicrobial and anti-tubercular activity of 5-Nitro 2-Thiophene 
carboxaldehyde compound has been screened. 
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AIM AND OBJECTIVES 
 
 
 To evaluate the antibacterial activity of 5-Nitro 2-thiophene carboxaldehyde compound by 
Agar dilution and Agar diffusion method. 
 
 To evaluate the antifungal activity of 5-Nitro 2-thiophene carboxaldehyde compound by Agar 
dilution method. 
 
 To evaluate the anti-tubercular activity of 5-Nitro 2-thiophene carboxaldehyde compound by 
Microplate Alamar Blue Assay method (MABA) using H37Rv tubercular cell lines. 
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COMPOUND PROFILE 
 
 
 
Molecular Formula : C5H3NO3S 
Molecular Weight    :157.15 gm/mol. 
APPEARANCE: 
Colour                                              : Yellow to Brown 
Form                                                            : Solid (Crystals, Fibres, crystalline powder) 
Melting Point                                              : 75 - 77ºC – lit. 
Purity                                                          : > 97.5% 
Solubility 10mg/ml (1%), Acetone              : Clear 
Solubility Colour                                          : Colourless to Yellow colour 
Incompatible Material                                   : Strong oxidizing agent, strong base  
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   5-NITRO 2-THIOPHENE CARBOXALDEYDE  
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Description: 
 5-Nitro 2-Thiophene carboxaldehyde is an aromatic heterocyclic compound consisting of four 
carbon atoms and one sulfur atom in a five membered ring with Nitro group at the 5th position.  
Thiophene was discovered by Victor Meyer in 1883 as a contaminant in benzene.(12) 
 Thiophene was observed that isatin forms a blue dye, if it is mixed with sulfuric acid and 
crude benzene.  Victor Mayer was able to isolate the substance responsible for this reaction from 
benzene.  This newly heterocyclic compound was thiophene.(13) 
 
 Thiophenes are important class of heterocyclic compounds and are recurring building blocks 
in organic chemistry with applications in pharmaceutical.  The benzene ring of a biologically active 
compound may often be replaced by a thiophene without loss of activity.(14)  Thiophene and its 
derivatives occur in petroleum, sometimes in concentration upto 1-3 %.   The thiophenic content of 
liquids from oil and coal is removed via the hydrodesulphurization (HDS) process. 
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Therapeutic importance: 
 In Medicinal chemistry, Thiophene derivatives have been well known for their therapeutic 
applications.  Many thiophene derivatives have been developed as chemotherapeutic agents and are 
widely used.  Thiophene nucleus is one of the most important heterocycles exhibiting remarkable 
pharmacological activities. 
 Over the recent years there has been an increasing interest in the medical field of thiophene 
because of their biological significance. 
1. Analgesic(15) 
2. Antimalarial(16)  
3. Anticonvulsant(17) 
4. Antifungal(18) 
5. Antihistaminic(19) 
6. Anti-inflammatory(20) 
7. Antitumor(21) 
8. Antiviral(22) 
9. Diuretic(23) 
10. Insecticidal(24) 
11. Antipsychotic(25) 
  In the June 16, 2013, online edition of the Journal Chemical Biology revealed that 
treatment of Mycobacterium tuberculosis with an experimental thiophene drug was bactericidal and 
equivalent to treatment with first line drug isoniazid, but was less likely to permit emergent resistant, 
combined isoniazid and thiophene treatment resulted in complete inhibition of Mycobacterium 
tuberculosis growth.  
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REVIEW OF LITRATURE: 
Anti-inflammatory activity: 
Sahar Mohamed Ibrahim BADR, et al., Synthesis and anti-inflammatory activity of novel 
2,5-disubstituted thiophene derivatives were studied.  New series of 2,5-disubstituted thiophenes 
were synthesized.  Thiosemicarbazones 1a-b were reacted with various reagents, such as diethyl-2-
bromomalonate, ethyl-2-chloroacetoacetate, thioglycolic acid, 4-substituted phenacyl bromides, and 
acetic anhydride, to afford heterocyclic substituted thiophene derivatives 2a-b, 3a-b, 4a-b, 5a-b, 6a-b, 
and 7a-b, respectively.  Moreover, cyclization of the key intermediate 1b with chloroacetic acid 
yielded thiazolidine 9, which on reaction with appropriate aromatic aldehydes afforded the 
corresponding arylidene derivatives 10a-f.  Finally, reaction of N – arylidene cyanoacetohydrazide 11 
with sulfur and phenyl isothiocyanate yielded thiazoline derivative 12, which on treatment with tri 
ethyl ortho formate and acetic anhydride afforded thiazolo (4,5-d) pyrimidinone derivative 13.  Some 
of the newly synthesized compounds showed promising anti-inflammatory activity. 
Antimalarial activity: 
Tedlouti et al., Evaluation of the antimalarial activity of new compound against Plasmodium 
falsiparum  invitro and Plasmodium berghei  invivo, on mice experimentally.  These hydrazones were 
obtained by condensation of appropriate hydroxines with thiophene 2-carboxaldehyde, thiophene 2-
carboxaldehyde, 5-Nitro thiophene 2-carboxaldehyde.  The compound of series 3,5-nitrothiophene 
2-carboxaldehyde presented significant effects both invitro and invivo methods.  
Anti-Inflammatory and analgesic activity: 
Sondhi, S.M. et al., Synthesis of some thiophene, imidazole and pyridine derivatives 
exhibiting good anti-inflammatory and analgesic activities were studied.  A series of thiophene 
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derivatives 1a-d and 2a-c were synthesized by condensation of 5-Nitro 2-Thiophene carboxaldehyde 
with mono and diamine respectively.  Compound 1b and 2c exhibited good anti-inflammatory 
activity. 
Antimicrobial and antitumor activity:  
Etaiw S.E. et al., Synthesis, spectral, antimicrobial and antitumor assessment of Schiff base 
derived from 2-amino benzthiazole and its transition metal complexes were studied.  N-(thiophene-2-
yl methylene) benzo [d] thiazole-2-amine Schiff base (L) derived from 2-amino benzthiazole and 2-
thiophene carboxaldehyde and its complexes with Cu(II), Ni(II), and Zn(II) were prepared.  In view 
of the biological activity of the Schiff base and its complexes, it has been observed that the 
antimicrobial activity of the Schiff base increased on complexation with the metal ions and having 
significant invitro antitumor activity. 
Anticonvulsant and antiparkinsonism activity: 
Abdel-Galil E. Amr. et al., Synthesis and reactions of some fused oxazinone, pyridinone, 
thiopyrimidone and triazone derivatives with a thiophene ring to offerd the corresponding 
thioglycolic acid pyrimidone derivatives.  The pharmacological screening showed that many of these 
obtained compounds have good analgesic, anticonvulsant and anti-parkinsonism activities 
comparable voltarene, carbamazepine and benzotropine as reference drugs. 
Antitubercular activity: 
Joshi H.S. et al., Synthesis of some New Thiosemicarbazide and 1, 3, 4-Thiadiazole 
Heterocycles bearing [b] Thiophene nucleus as a potent Antitubercular and Antimicrobial Agents 
were studied.  Reaction of 2-hydrazinocarbonyl-3-chloro-5phenoxy-benzo[b] thiophene with different 
                                                                         Review of Literature                             
 
Institute of Pharmacology, MMC Page 12 
 
substituted phenyl isothiocyanate gave N-substituted arylthiosemicarbazide derivatives (1a-h).  1,3,4-
Thiadiazole derivatives (2a-h) were prepared by the cyclization of arylthiosemicarbazides (1a-h) with 
concentrated sulphuric acid.  All the compounds were screened for their antitubercular activity 
against Mycobacterium tuberculosis (H37Rv) and antimicrobial activity against various 
microorganisms. 
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ANTI MICROBIAL ACTIVITY 
ANTIBACTERIAL ACTIVITY: 
 The science dealing with the study of the prevention and treatment of disease caused by 
micro-organisms is known as medical microbiology.  Its sub disciplines are virology (study of 
viruses), bacteriology (study of bacteria), mycology (study of fungi), phycology (study of algae) and 
protozology (study of protozoa).  For the treatment of diseases inhibitory chemicals employed to kill 
micro-organisms or prevent their growth, are called antimicrobials agents.  These are classified 
according to their application and spectrum of activity, as germicides that kill micro-organisms, 
whereas micro-biostatic agents inhibit the growth of pathogens and enable the leucocytes and other 
defense mechanism of the host to cope up with static invaders.  The germicides may exhibit selective 
toxicity depending on their spectrum of activity.  They may act as viricides (killing viruses), 
bactericides (killing bacteria), algicides (killing algae) or fungicides (killing fungi). 
 Paul Ehrlich used the term chemotherapy for curing the infectious disease without injury to 
the host’s tissue, known as chemotherapeutic agents such as antibacterial, antiprotosoal, antiviral, 
antineoplastic, antitubercular and antifungal agents.  Later on, Domagk (1953) prepared an important 
chemotherapeutic agent sulfanilamide. 
BACTERIA: 
 The bacteria are microscope organisms with relatively simple and primitive forms of 
prokaryotic type.  Danish Physician Christian Grams, discovered the differential staining technique 
known as Gram staining, which differentiates the bacteria into two groups “Gram positive” and 
“Gram negative”, Gram positive bacteria retains the crystal violet and resist decolorization with 
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acetone or alcohol and hence appear deep violet in colour; while Gram negative bacteria, which loose 
the crystal violet, are counter-stained by saffranin and hence appear red in color.(26) 
 These two groups of bacteria are recently classified into four different categories as follows: 
(1) The world of bacteria I : “Ordinary” Gram negative bacteria 
(2) The world of bacteria II : “Ordinary” Gram positive bacteria 
(3) The world of bacteria III : “Bacteria” with unusual properties 
(4) The world of bacteria IV : Gram positive filamentous bacteria of complex                  
morphology. 
CLASSIFICATION OF ANTIBACTERIAL AGNETS 
The antibacterial agents are classified in three categories: 
I. Antibiotics chemotherapeutic agents. 
II. Non-antibiotic chemotherapeutic agents 
(Disinfectants, antiseptics and preservatives 
III. Immunological products. 
ANTIBIOTICS: 
 They are produced by micro-organisms or they might be fully or partly prepared by chemical 
synthesis.  They inhibit the growth of micro-organisms in minimal concentrations.  Antibiotics may 
be of microbial origin or purely synthetic or semi synthetic.(27)  They can be classified by manner of 
mechanisms of action. 
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CLASSIFICATION OF ANTIBIOTICS ACCORDING TO THEIR MECHANISMS OF 
ACTION :( Berdy, 1974).(28) Table - 1 
S.NO MECHANISM OF ACTION EXAMPLE 
1 Inhibit cell wall synthesis Penicillins, Cephalosporins, Cycloserine, 
Vancomycin, Bacitracin 
2 Cause leakage form cell membranes Polymyxins, Colistin, Bacitracin, 
Amphotericin-B, Nystatin, Hamycin  
3 Inhibit protein synthesis Tetracyclins, Chloramphenical, Erythromycin, 
Clindamycin, Linezolid. 
4 Cause misreading of mRNA code and 
affect permeability 
Aminoglycosides: Streptomycin, Gentamycin, 
Amikacin, etc 
5 Inhibit DNA gyrase Fluoroquinolones: Ciprofloxacin, Ofloxacin 
Norfloxacin, Pefloxacin, etc 
6 Interfere with DNA function Rifampicin, Metronidazole 
7 Interfere with DNA synthesis Idoxuridine, Acyclovir, Zidovudine 
8 Interfere with intermediary metabolism Sulfonamides, Sulfones, PAS, Trimethoprim, 
Pyrimethamine, Ethambutol 
 
 Synthetic antimicrobial agents include sulfonamides, Diamino pyrimidine derivatives, 
antitubercular compounds, nitrofuran compounds, 4-quinoline antibacterials, imidazole derivatives, 
flucytosine etc. 
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(II) NON-ANTIBIOTICS CHEMOTHERAPEUTIC AGENTS: 
  The second category of antibacterial agents includes non-antibiotic chemotherapeutic 
agents which are as follows: 
1. Acids and their derivatives 
Some organic acids such as ascorbic, benzoic, lactic and propionic acids are used 
for preserving food and pharmaceuticals.  Salicylic acid has strong antiseptic and germicidal 
properties as it is a carboxylated phenol.  The presence of –COOH group appears to enhance 
the antiseptic property and to decrease the destructive effect.  Benzoic acid is used externally 
as an antiseptic and is employed in lotion and ointment.  Benzoic acid and salicylic acid are 
used to control fungi that cause disease such as athlete’s foot.  Benzoic acid and sodium 
benzoate are used as antifungal preservatives.  Mandolic acid possesses good bacteriostatic 
and bactericidal properties. 
2. Alcohols and related compounds 
They are bactericidal and fungicidal, but are not effective against endospores and some 
viruses.  Various alcohols and their derivatives have been used as antiseptics e.g. ethanol and 
propanol.  The antibacterial value of straight chain alcohols increases with an increase in the 
molecular weight and beyond C8- the activity begins to fall off.  The isomeric alcohol shows a 
drop in activity from primary, secondary to tertiary.  Ethanol has extremely numerous uses in 
Pharmacy. 
3. Chlorination and compound containing chlorine: 
Chlorination is extensively used to disinfect drinking water, swimming pools and 
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for the treatment of effluent from industries.  Robert Koch in 1981 first referred to the 
bactericidal properties of hypochlorites.  N-chloro compounds are represented by amides, 
imides and amidines wherein one or more hydrogen atoms are replaced by chlorine. 
4. Iodine containing compounds: 
Iodine containing compounds are widely used as antiseptic, fungicide and amoebicide.  
Iodophores are used as disinfectants and antiseptics.  The soaps used for surgical scrubs often 
contain iodophores. 
5. Heavy metals: 
Heavy metals such as silver, copper, mercury and zinc have antimicrobial properties 
and are used in disinfectant and antiseptic formulations.  Mercurochrome and Merthiolate are 
applied to skin after minor wounds.  Zinc is used in antifungal antiseptics.  Copper sulfate is 
used as algicides. 
6. Oxidizing agents: 
Their value as antiseptics depends on the liberation of oxygen and all are organic 
compounds. 
7. Dyes: 
Organic dyes have been extensively used as antibacterial agents.  Their medical 
significance was first recognized by Churchman(29) in 1912.  He reported inhibitory effect of 
Crystal violet on Gram-positive organism.  The acridines exert bactericidal and bacteriostatic 
action against both Gram-positive and Gram-negative organisms. 
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8. 8-Hydroxyquinolines: 
8-Hydroxyquinolines or oxine is unique among the isomeric hydroxyl-quinolines, for it 
alone exhibits antimicrobial activity.  This attributes to its ability to chelate metals,(30) which 
the other isomers do not exhibit. 
9. Surface active agents: 
Soaps and detergents are used to remove microbes mechanically from the skin surface.  
Anionic detergents remove microbes mechanically; Cationic detergents have antimicrobial 
activities and can be used as disinfectants and antiseptics. 
(III) IMMUNOLOGICAL PRODUCTS: 
  Certain immunological products such as vaccines and monoclonal antibodies are used 
to control the diseases as a prophylactic measure. 
Mode of action: 
 Antimicrobial drugs interfere chemically with the synthesis of function of vital components of 
microorganisms, the cellular structure and functions of eukaryotic cells of the human body.  These 
differences provide us with selective toxicity of chemotherapeutic agents against bacteria. 
 Antimicrobial drugs may either kill microorganisms outright or simply prevent their growth.  
There are various ways in which these agents exhibit their antimicrobial activity.(31) They may inhibit 
1. Cell-wall synthesis 
2. Protein synthesis 
3. Nucleic acid synthesis 
4. Enzymatic activity 
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5. Folate metabolism or 
6. Damage cytoplasmic membrane  
Bacteriostatic dyes:  
 Stearn and Stearn(32) attributed the bacteriostatic activity to triphenylmethane dyes.  Fischer 
and Munzo(33) have found the relationship between their structure and effectiveness of such dyes. 
 A number of drugs are metal-binding agents.  The chelates are the active form of drugs.  The 
site of action within the cell or on the cell surface has not been estabilished.  The site of action of 
oxine and its analogs has been suggested inside the bacterial cell(34) or on cell surface.(35) 
Detoxification of antibacterials: 
 p-Aminobenzoic acid is a growth factor for certain micro-organisms and competitively 
inhibits the bacteriostatic action of sulfonamides.  The metabolites identified in man are p-amino-
benzoylglucoronide; p-aminohippuric acid, p-acetylaminobenzoic acid. 8-Hydroxyquinoline (oxine) 
and 4-hydroxyquinoline are excerted as sulfate esters or glucorinides. 
ANTIFUNGAL ACTIVITY: 
There are perhaps over 10,000 species of fungi, but less than 100 cause diseases in human.(36)  
Fungi may cause benign, but unsightly infections of the skin, nail or hair, relatively trivial infection of 
mucous membranes (thrush) or systemic infection causing progressive often fatal disease. 
CLASSIFICTION OF MEDICALLY IMPORTANT FUNGI:(37) 
1. True yeasts (e.g. Cryptococcus neoformans) 
2. Yeast like fungi that produce a pseudomycelium (e.g. Candida albicans) 
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3. Filamentous fungi that produce a true mycelium (e.g. Aspergillus fumigatus) 
4. Dimorphic fungi that grow as yeast or filamentous fungi depending on the cultural conditions 
(e.g. Histoplasma capsulatum) 
ANTIBIOTIC RESISTANCE: 
 Antibiotics are extremely important in medicine, but unfortunately bacteria are capable of 
developing resistance to them.  Antibiotic-resistance bacteria are germs that are not killed by 
commonly used antibiotics.  When bacteria are exposed to the same antibiotics over and over, the 
bacteria can change and are no longer affected by the drug.  Bacteria have number of ways how they 
become antibiotic resistance.  For example, they possess an internal mechanism of changing their 
structure, so the antibiotic no longer works, they develop ways to inactivate or neutralize the 
antibiotic.  Also bacteria can transfer the genes coding for antibiotic resistance between them, making 
it possible for bacteria never exposed to an antibiotic to acquire resistance from those which have.  
The problem of antibiotic resistance is worsened when antibiotics are used to treat disorders in which 
they have no efficacy (e.g. antibiotics are not effective against infections caused by viruses), and 
when they are used widely as prophylaxis rather than treatment.  Resistance to antibiotics possesses a 
serious and growing problem, because some infectious diseases are becoming more difficult to treat.  
Resistant bacteria do not respond to the antibiotics and continue to cause infection.  Some of these 
resistant bacteria can be treated with more powerful medicines, but there some infections that are 
difficult to cure even with new or experimental drugs.(38)  
 The incidence of multidrug-resistant pathogenic bacteria is increasing.  On additional reason 
for developing new antibiotics is related to their own toxicity.  As with other therapeutic agents, the 
use of antibiotics may also cause side effects in patients.  These include mild reactions such as 
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stomach upset, vomiting and diarrhoea (cephalosporins, macrolides, penicillins and tetracyclines), 
rash, other mild and severe allergic reactions (cephalosporins and penicillins), sensitivity to sunlight 
(tetracyclines), nervousness tremors and seizures (quinolones).  Some side effects are more severe not 
depending on the antibiotic may disrupt the hearing function (aminoglycosides), kidneys 
(aminoglycosides and polypeptides) or liver (rifampin).  To counteract the resistance by microbes 
there is a need to invent new drugs, which are more safe and effective. 
 In order to combat the microbial infections anti-microbial agents are frequently used 
concurrently i.e the combined use of antimicrobials with following objectives, 
 To prevent emergence of resistance 
 To lower the adverse or side effects 
 To have a synergistic effect 
 To broaden the antimicrobial spectrum 
Since micro-organisms develop rapid resistance there is an ample scope for the development 
of antibacterial agents that are active against resistant bacteria.(39) 
5-nitro-2-thiophene carboxaldehyde is reported to have antimicrobial activity.  Hence it was 
proposed to study the antimicrobial activity against 5 bacterial organisms and 2 fungal organisms 
which are as follows.   
Antibacterial activity was carried against 5 organisms: 
1. Staphylococcus aureus (Gram positive) 
2. Enterococcus(Gram positive) 
3. Escherichia coli(Gram negative ) 
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4. Pseudomonas aeruginosa(Gram negative) 
5. Salmonella Typhi(Gram negative) 
Antifungal activity was carried against 2 organisms: 
1. Candida albicans 
2. Aspergillus flavus 
Staphylococcus aureus 
 It is Gram-positive cocci, ovoid or spheroidal, non-motile, arranged in group of clusters; they 
grow on nutrient agar and produce colonies, which are golden yellow, white or lemon yellow in 
colour. Pathogenic strains produce, coagulated and ferment glucose lactose, mannitol with production 
acid, liquefy gelation and produce pus in the lesion.(40) 
Infections:  
1. Septic arthritis 
2. Endocartitis 
3. Pneumonia 
4. Atopic dermatitis(41) 
Enterococcus: 
 It is a Gram-positive cocci that occur in short chain which is facultative anaerobic organisms 
(i.e) they are capable of cellular respiration in both oxygen-rich and oxygen-poor environments.(42)  
They are tolerant to wide range of environmental condition.(28) 
Infections: 
1. Urinary tract infection 
                                                                         Review of Literature                             
 
Institute of Pharmacology, MMC Page 23 
 
2. Bacteremia 
3. Bacterial endocarditis 
4. Diverticculitis and meningitis(43) 
Escherichia coli: 
 They are Gram-negative rods, motile with peritrichate flagella or non motile.  They do not 
form spores.  All are commonly found in intestine of warm blooded organisms.  It causes food 
contamination.  It is used for producing the vitamin K2, preventing the estabilishment of pathogenic 
bacteria, used as plasmid and restriction enzyme to create Recombinant DNA and which is ideal 
organisms to test environmental sample for fecal contamination. 
Infections: 
1. Gastroenteritis 
2. Urinary tract infection 
3. Neonatal meningitis 
4. Hemolytic uremic syndrome 
5. Peritonitis 
6. Mastitis 
7. Septicemia 
8. Pneumonia(44) 
Pseudomonas aureginosa:  
 They are Gram-negative, aerobic short rod shape coccobacilli with unipolar motility.  
Organisms are non-sporulating and non-capsulated, however, few strains possess slime layer of up of 
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polysaccharides.  It is identified as pearlescence appearance and grap like or tortilla like odour invitro 
studies.  It is usually found widely in the environment such as soil, water and plants.  It mainly causes 
nasocomical infections. 
Infections: 
1. Pneumonia 
2. Meningitis 
3. Endocartitis 
4. Osteomyelitis  
5. Gastrointestinal tract infections(Diarrhoea, enteritis, enterocolitis) 
6. Skin and soft tissue infections (ecthyma gangrenosum) 
Salmonalla typhi: 
 Salmonalla is a Gram-negative, rod-shaped, non-spore forming, motile enterobacteria, 
facultative anaerobes belong to the family of enterobacteriacea, which is susceptible to various 
antibiotics. 
Infections: 
1. Typhoid fever 
2. Diarrhoea(45) 
Candida albicans: 
 Candida species reproduce by yeast like budding cells but they also show formation of 
pseudomycellum.  These pseudomycellum are chains of elongated cells formed from buds and the 
buds elongated without breaking of the mother cell.  They are very fragile and separate easily.  
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Mycelia also form by the elongation of the germ tube by a mother cell.  It may remain as a 
commensal of the mucous membrane with or without causing any pathogenic changes to the deeper 
tissues of the same fungus may cause pathological lesion of the skin.  Such a fungus under favorable 
conditions can cause superficial, intermediate of deep mycoses depending on the condition of the 
host. 
Infections: 
1. Oral candidiasis, oropharyngeal candidiasis 
2. Vulvovaginal yeast infection 
3. Diaper rash 
4. Candidemia(46) 
Aspergillus flavus: 
 The Aspergilclli are widespread in nature, being found in fruits, vegetables and other 
substances, which may provide nutrient.  Some species are involved in food spoilage.  They are 
important economically because they are used in a number of industrial fermentations, including the 
production of citric acid and gluconic acid.  Aspergilli grow in high concentrations of sugar and salt, 
indicating that they can extract water required for their growth from relatively dry substances.(47) 
ANTITUBERCULOSIS: 
MYCOBACTERIA 
 The genus Mycobacterium belongs to the order Actinomycetales and the family 
Mycobacteriaceae; it is characterized by non-motile, non-sporulating rods that resist decolorization 
with acidified organic solvents and alcohol.  For this reason, they are also called acid-fast bacteria.  
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Some mycobacterial species are pathogenic for humans: they so called Mycobacterium complex 
includes M.tuberculosis, M. bovis, and M. africanum.  Mycobacterium macroti is pathogenic for 
voles, field mice, and other rodents, but it was considered nonpathogenic in humans.  However, in 
recent years, it has been demonstrated that it can cause disease in immune-suppressed, and 
particularly, in HIV positive patients.  Mycobacterium leprae, pathogenic for man, was considered of 
uncertain taxonomy for some time, but now is definitely classified among Mycobacteria.  The study 
of its genome has contributed to clarify its position in this genus.  The development of recombinant 
DNA technology has allowed us to define better the species belonging to these groups, but the 
general definition still does not seem satisfactory.  A common definition in the recent years has been 
“Mycobacteria other than tuberculosis” (MOTT), but now “Non-Tuberculous Mycobacteria” (NTM) 
is preferred. 
 The most recent and appropriate grouping of these organisms, proposed by the American 
Thoracic Society, is based on the type of clinical disease they produce: Pulmonary disease, 
lymphadenitis, cutaneous disease, and disseminated disease.  The term mycobacteriosis is proposed 
for the diseases caused by these organisms.(48) 
PATHOGENESIS AND EPIDEMIOLOGY 
           Tuberculosis is sometimes an acute but more frequently a chronic communicable disease that 
derives its character from several properties of the tubercle bacillus, which in contrast with many 
common bacterial pathogens, multiplies slowly, does not produce exotoxins, and does not stimulate 
an early reaction from the host. The tubercle bacillus is also an intracellular parasite, living and 
multiplying inside macrophages.  
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           Chronic pulmonary tuberculosis in adults may be due to reactivation of the primary infection 
or to exogenous re-infection. A typical characteristic of tuberculosis is the formation in the infected 
tissue nodular formations called tubercles, which can have different sizes and different modes of 
diffusion, giving rise to various clinical forms called military, infiltrate, lobar tuberculosis, and so on. 
The disease progresses by means of ulceration, cessation and cavitations, with bronchogenic spread 
of infectious material. Healing may occur at any stage of the disease by processes of resolution, 
fibrosis, and calcification. 
             Control of the disease has been achieved in part through mass vaccination with BCG   
(Bacillus of Calmette and Guerin, an attenuated strain of M. tuberculosis bovis).(49) 
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Figure - 1 
Mycobacterium Tuberculosis Cell structure 
 
Figure - 2 
 
                                                                         Review of Literature                             
 
Institute of Pharmacology, MMC Page 29 
 
H37Rv cell line:  
 Mycobacterium tuberculosis is a highly successful pathogens and it’s successfully relies on its 
ability to utilize macrophages for its replication and, more importantly, the macrophages should 
remain viable to host the mycobacterium.  Despite the fact that these phagocytes are usually very 
effective in internalizing and clearing most of the bacteria, Mycobacterium tuberculosis H37Rv has 
evolved a number of very effective survival strategies, including 
a) The inhibition of phagosome-lysosome fusion. 
b) The inhibition of phogosome acidification 
c) The recruitment and retention of tryptophan aspartate containing coat protein on phagosomes 
to prevent their delivery to the lysosomes. 
d) The expression of members of the host induced repetitative glycine rich protein family of 
proteins. 
However, the mechanisms by which Mycobacterium tuberculosis H37Rv enters the host cell, 
circumvents host defenses and spreads to neighboring cell are not completely understood.(50) 
TUBERCULOSIS: 
 Tuberculosis (TB) is a contagious disease and is at least as old as mankind caused by 
mycobacteria, mainly mycobacterium tuberculosis.  However, still TB continues to be the second 
largest killer of adults worldwide, the being HIV.  Mycobacteria, is a slow-growing bacteria that 
thrive in areas of the body that are rich in blood and oxygen.  TB in the lungs is easily spread to other 
people through coughing or laughing. Tuberculosis is a curable and controllable disease. 
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 Only people who are sick with TB in their lungs are infectious.  Left untreated, each person 
with active TB disease will infect on average between 10 and 15 people every year.  But people 
infected with TB bacilli will not necessarily become sick with the disease.  The immune system 
“walls off” the TB bacilli which can lie dormant for years.  When someone’s immune system is 
weakened, the chances of becoming sick are greater.(51) 
INCIDENCE OF TB: 
The global burden of tuberculosis (TB) is staggering.  An estimated 8.3 million people 
developed active TB and nearly 2 million people died of TB in 2000 alone. 
 Tuberculosis (TB) kills two million people a year-one person every 15 seconds.  The global 
incidence of TB disease is rising by 1% annually.  Most importantly, the emergence of multidrug-
resistant TB (MDR-TB) is posing a new challenge.  Approximately 44,600 new MDR-TB patients 
are being reported in India every year.  Globally, India and china are responsible for about 50 percent 
of the MDR-TB cases. 
 An estimated 1 billion people will be newly infected between 2000 and 2020, 200 million will 
fall ill and 35 million will die.  TB is a leading cause of death among living with HIV/AIDS.(52) 
Risk factors for TB include the following: 
 HIV infection 
 Low socioeconomic status 
 Alcoholism 
 Homelessness 
 Crowded living conditions 
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 Diseases that weaken the immune system 
 Migration from a country with a high number of cases and health-care workers(53) 
Symptoms of Tuberculosis: 
1. Poor appetite 
2. Night sweets 
3. Muscle weakness 
4. Fever 
5. Dry cough 
6. Weight loss 
TRANSMISSION: 
Spreads through the air when a person with active TB 
 Coughs 
 Speaks 
 Laughs 
 Sneezes 
 Sings 
Another person breathes in the bacteria and become infected 
Some signs of TB disease are: 
• A bad cough that lasts 3 weeks or longer 
• Pain in the chest 
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• Coughing up blood or phlegm from deep inside the lungs 
• Weakness or feeling very tired 
• Losing weight very kind 
• Having no appetite 
• Chills and fever 
• Sweating at night or when you are sleeping(54) 
CURRENT THERAPY (55) 
 Drugs used in the treatment of tuberculosis can be divided into two groups. 
First-line: 
 The first line agents include isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), 
streptomycin and EMB.  These agents combine the greatest level efficacy with an acceptable degree 
of toxicity. 
Second-line 
 These agents include ofloxacin, ciprofloxacin, ethionamide, para amino salicylic acid, 
cycloserin, amikacin, kanamycin and capreomycin.  Because of microbial resistance or patient related 
factors such as HIV infection, it may be necessary to resort to second line drugs in addition. 
Depending upon Chemical Structure Classification:- 
 Aminosalicylates and derivatives: PAS, Benzoyl PAS 
 Heterocyclic amides: Pyrazinamide, Ethionamide, Prothionamide 
 Hydrazides and derivatives: Isoniazid (INH), Iproniazid, sulfoniazid 
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 Thiourea/thiosemicarbazone derivatives: Thioacetazone, etocarlide 
 Ethylene diamine derivatives: D-ethambutol 
 Rimino Phenazine derivatives: Clofazimine 
 Antitubercular antibiotics 
• Aminoglycosides: Streptomycin, Kanamycin, Amikacin 
• Polypeptides: Capreomycin, Viomycin 
• Ansamycin derivatives: Rifamycin B, Rifamycin, Rifabutin 
• Isoxazolidone derivatives: Cycloserine 
 Newer Anti-tubercular agents (Investigational Drugs) 
• Fluoroquinolones: Sparfloxacin, Gatifloxacin Moxifloxacin 
• Macrolide antibiotics: Clarithromycin, Azithromycin 
• Nitroimidazopyrans: PA-824 
Directly observed treatment-short course therapy (DOTS) 
The magnitude of human suffering forced the government of India to launch to – the Revise National 
Tuberculosis Control Program (RNTCP) in 1993.  This is an application to India of the WHO 
recommended, “Directly Observer Treatment – Short Course Therapy (DOTS)”.  DOTS is a strategy 
documented to be extra ordinarily effective worldwide in Europe, in the USA and in south East Asia. 
CURRENT REGIMEN (56) 
 The recommended first-line regimen consists of isoniazid (H), rifampin (R), pyrazinamide 
(Z), and ethambutol (E) (HRZE) for 2 months daily or thrice weekly, followed by 4 months of HR or 
six months of HE.  Totally patient has to take drugs for 6 months 
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CONCERN OVER CURRENT REGIMEN :(57) 
 The main problems encountered in implementing these regimens are, 
1. Prolonged course of therapy and poor compliance 
2. Drug interactions 
3. Adverse events 
Length of treatment: 
6 months long duration of TB regimen is not patient friendly and most of the patients do not 
complete the treatment.  This has led to the emergence of multi-and extensively drug resistant TB 
strains, known as MDR-TB and XDR-TB, respectively. 
 MDR-TB is defined as resistance to both H and R, and may be any number of other anti-TB 
drugs. 
For H resistance – RZE given for 12 months is recommended. 
For H+ resistance – ZE+S/ Kmc/ Am/ Cpr + Cipro/ Ofl ± Etm could used. 
 XDR-TB is defined as resistant to H, R, a FQ, one of Kmc/ Am/ Cpr with or without any 
number of other drugs.  The XDR-TB is virtually untreatable; mortality is high, particularly 
among HIV positive patients. 
Drug interactions: 
 Rifamipicin reduces the concentration of most ARVs, due to enzyme induction when TB 
regimen used along with ARV drugs to treat HIV-TB co-infection.  Due to drug interactions of R 
with many antiretroviral drugs (ARVs), implementation of DOTS remains problematic in people co-
infected with HIV and TB. 
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Adverse events: 
 Though TB drugs are generally well tolerated, they can cause significant adverse effects and 
in some cases are contraindicated.  Rifampicin and Isoniazid causes hepatitis and pheripheral 
neuropathy respectively. 
 The implementation of TB chemotherapy in the field in the field would be much easier if the 
duration of therapy could be shortened without sacrificing efficacy, a feat that will require at least one 
new anti-tuberculosis drug.  To address these emerging challenges, WHO has been initiating new 
drug development ideally to shorten and simplify the duration of TB Treatment and address MDR-
TB. 
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Miladis Isabel Camacho-Pozo et al., (2010) found that antimicrobial activity of extracts of 
Tamarindus indica L. leaves were tested against Bacillus subtilis, Enterococcus faecalis, 
staphylococcus aureus, Escherichia coli, Salmonella typhimurium, Pseudomonas aeruginosa and 
Candida albicans.  The essential oil exhibited a good antimicrobial spectrum when pure, but its 
relative low concentrations in common folk preparations do not allow for any good activity in these 
extracts.(58) 
Bibul Biswas et al., (2013) was found that the antimicrobial potential of Psidium guajava leaf 
extracts of different solvent were tested against Escherichia coli, Salmonella enteritidis, 
Staphylococcus aureus and Bacillus cereus by well-diffusion method employing 50 µL extract per 
well.  On the basis of the present finding, guava leaf extract might be a good candidate in the search 
for a natural antimicrobial agent.(59) 
IE Oboh et al., (2007) was found that the ethonolic extract of Sida acuta burm.f. shows significant 
inhibitory activity against standard strains and clinical isolates of Staphylococcus aureus, Bacillus 
subtilis and Streptococcus feacalis.  The MIC values obtained using the Agar-dilution test ranged 
from 5.0 mg/ml – 10.0 mg/ml.  Neither the concentrated extract nor its dilutions inhibited Escherichia 
coli, Klebsiella pneumonia, Pseudomonas aeruginosa and Candida albicans.(60) 
Mendoza-Aguilar et al., (2012) found that the use of the Microplate Alamar Blue Assay (MABA) to 
assess the susceptibility of Mycobacterium tuberculosis to anti-tubercular and other drugs.(61) 
Ibrahim T et al., (2012) found that anti-TB activity of Sterculia setigera Del., Leaves (Sterculiaceae).  
Antitubercular activity of S. setigera was investigated in-vitro on a micro-scale using the Alamar Blue 
Assay.  Three of four successive solvent extractions of the plant leaves extracts inhibited the growth 
of a virulent strain of Mycobacterium tuberculosis, H37Rv in the concentrations tested (1 – 128 
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µg/ml).  The Minimum Inhibitory Concentration (MIC) determined for the hexane, dichloromethane 
and ethyl acetate extracts were 84 µg/ml, 62 µg/ml and 128 µg/ml respectively.(62) 
Sreenivasulu Munna et al., (2014) found that antitubercular effect of n-Hexane, Chloroform, 
Ethanol extracts was prepared from whole plant of Actiniopteris radiate Linn was evaluated against 
Mycobacterium tuberculae using Microplate Alamar Blue Assay (MABA).  Minimum Inhibitory 
Concentration (MIC) was taken to assess antitubercular activity.  The result shown that chloroform 
extract have more significant antitubercular activity as compared to n-Hexane and ethanolic extracts.  
Pyrazinamide and Streptomycin was taken as standard drugs.(63) 
S. Chand Basha et al., (2012) found that antitubercular effect of n-Hexane, Chloroform, Ethanol 
extracts was prepared from leaves of Rhinacanthus nasutus (k) was evaluated against Mycobacterium 
tuberculosis using Microplate Alamar Blue Assay (MABA).  Minimum Inhibitory Concentration 
(MIC) was taken to assess antitubercular activity.  The result shows that ethanolic extract have more 
significant antitubercular activity as compared to n-Hexane, chloroform extracts.  Pyrazinamide and 
Streptomycin was taken as standard drugs.(64) 
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Plan of Work 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Standard drug used: Ciprofloxacin, Gentamycin, Amikacin 
 
5-NITRO 2-THIOPHENE CARBOXALDEHYDE 
ANTI-MICROBIAL ACTIVITY ANTI-TUBERCULAR ACTIVITY 
ANTIBACTERIAL ACTIVITY 
ANTIFUNGAL ACTIVITY 
1. Minimum Inhibitory Concentration 
2. Zone of Inhibition 
a. S. aureus 
b. Enterococcus 
c. E.Coli 
d. P. aureginosa 
e. S. typhi 
Minimum Inhibitory Concentration 
Minimum Inhibitory Concentration 
a. Candida albicans 
b. Aspergillus flavus 
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MATERIALS AND METHODS 
COMPOUND NAME: 5-NITRO 2-THIOPHENE CARBOXALDEHYDE 
Product Number: 302295 
      The compound was purchased from Sigma-Aldrich Pvt Ltd, Bangalore, Karnataka. 
ANTIMICROBIAL ACTIVITY: 
1. Anti-bacterial activity 
2. Anti-fungal activity 
ANTIBACTERIAL ACTIVITY: 
 5-Nitro 3-Thiophene Carboxaldehyde were subjected to antibacterial studies against Gram 
positive and Gram negative organism. 
The organisms used were: 
1. Staphylococcus aureus 
2. Enterococcus 
3. Escherichia coli 
4. Peudomonas aureginosa 
5. Salmonalla typhi 
These organisms were maintained on Nutrient agar slopes in the Institute of Microbiology, MMC, 
Chennai and the organisms were confirmed by bio-chemical tests.  They were stored at 4ºC. 
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MEDIUM: 
Mullar Hinton agar media were obtained from Himedia Laboratory Mumbai – 400086, India. 
CHEMICAL AND REAGENTS: 
 The standard analytical grade reagents 
1. Dimethyl sulphoxide (DMSO) 
2. Water 
3. Ciprofloxacin 
4. Gentamycin 
5. Amikacin 
PREPARATION OF THE BACTERIAL SUSPENSION OF INACULATION :(65) 
 Few colonies of the pathogenic strains were picked and inoculated into 4ml of peptone water.  
These tubes were incubated for 2-5 hours to produce a bacterial suspension.  The suspension was then 
diluted if necessary with the saline solution to a density, visually equivalent to that of standard, 
prepared by adding 0.5ml of 1% barium chloride to 99.5 ml of 1% of sulphuric acid.  This suspension 
was then used for seeding. 
PREPARATION OF 5-Nitro 2-Thiophene carboxaldehyde FOR MICROBIAL ACTIVITY 
TESTING: 
 The compound dilution were prepared by dissolving the 5-Nitro 2-Thiophene carboxaldehyde 
compound in Dimethyl sulphoxide (DMSO) and make up the standard volume by distilled water, But 
Ciprofloxacin, Gentamycin and Amikacin are used as a standard drug which are dissolved and diluted 
by water. 
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Table – II: 
COMPOUND NAME CONCENTRATIO
N 
(mcg/ml) 
COMPOUND 
(ml) 
AGAR 
MEDIUM(ml) 
TOTAL 
MEDIUM 
VOLUME 
(ml) 
 
5-NITRO 2-
THIOPHENE 
CARBOXALDEHYDE 
1 µg/ml 1.2 13.8 15 
2 µg/ml 1.2 13.8 15 
3 µg/ml 1.2 13.8 15 
4 µg/ml 1.2 13.8 15 
5 µg/ml 1.2 13.8 15 
6 µg/ml 1.2 13.8 15 
7 µg/ml 1.2 13.8 15 
8 µg/ml 1.2 13.8 15 
9 µg/ml 1.2 13.8 15 
10 µg/ml 1.2 13.8 15 
 
PREPARATION OF MUELLER HITON AGAR MEDIUM: 
Materials required for the preparation of one liter of Mueller Hinton Agar medium, 
1. Beef infusion       300g 
2. Acid hydrolysate of casein     17.5g 
3. Starch        1.5g 
4. Agar        17g 
5. Distilled water      q.s. 
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The above constituents were weighed and dissolved in water, adjusted the pH 7.3±0.2.  The 
mixture was warmed on water bath till agar dissolved.  This was then sterilized in an autoclave at 15 
lbs pressure and 121ºC for fifteen minutes and used for sensitivity test.   
PREPARATION OF AGAR PLATES: 
 The plates were prepared using Mueller Hinton Agar medium and different compound (5-
nitro -2-thiophene carboxaldehyde, ciprofloxacin, gentamycin, amikacin) of various dilutions 
allowed to solidify and dry.  Then a loopful of different bacterial cultures were inoculated at the 
labeled spots.  All the plates were then incubated at 37ºC for 24 hours and results were recorded. 
INOCULUM’S PREPARATION:  
 The inoculum was standardized at 1.5x108 CFU/ml comparing with turbidity standard (0.5 
MacFarland tube). 
SWAB PREPARATION: 
 A supply of cotton swabs on wooden applicator sticks was prepared.  They were sterilized in 
tins, culture tubes, or on paper, either in the autoclave or by dry heat. 
ANTIFUNGAL ACTIVITY: 
 5-Nitro 2-Thiophene carboxaldehyde compound was subjected to antifungal activity studies: 
The fungal strains used are, 
1. Candida albicans 
2. Aspergillus flavus 
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These organisms are maintained on Sabouraud’s dextrose agar media and stored at 4ºC. 
MEDIUM: 
  Sabouraud’s dextrose agar media 
PREPARATION OF SABOURAUD’S DEXTROSE AGAR MEDIUM: 
 Materials required for the preparation of 1 liter of sabouraud’s dextrose media, 
1. Mycological peptone      10g 
2. Dextrose       40g 
3. Agar        15g 
4. Distilled water      q.s. 
5. Methylene blue dye       q.s 
The above constituents were weighed and dissolved in water. The mixture was warmed on water 
bath till agar dissolved and the final pH was adjusted to 5.5±0.2ºC. This was then sterilized in an 
autoclave at 15 lbs pressure at 121ºC for fifteen minutes, add the required amount of methylene blue 
dye, shake well and used for the sensitivity test. 
The dilutions were prepared by dissolving the 5-Nitro 2-Thiophene carboxaldehyde compound in 
Dimethyl sulphoxide and dilution done by using distilled water. 
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Table – III: 
 
COMPOUND NAME 
 
CONCENTRATION 
(mcg/ml) 
 
COMPOUND 
(ml) 
 
SABORAUD’S 
MEDIUM(ml) 
 TOTAL          
MEDIUM 
VOLUME 
(ml) 
 
5-NITRO 2-
THIOPHENE 
CARBOXALDEHYDE 
1 µg/ml 1.2 3.8 5 
3 µg/ml 1.2 3.8 5 
5 µg/ml 1.2 3.8 5 
7 µg/ml 1.2 3.8 5 
9 µg/ml 1.2 3.8 5 
10 µg/ml 1.2 3.8 5 
 
PREPARATION OF SABORAUD’S PLATES: 
 The plates were prepared using Saboraud’s dextrose agar medium and 5-nitro -2-thiophene 
carboxaldehyde of various dilutions allowed to solidify and dry.  Then a loopful of different bacterial 
cultures were inoculated at the labeled spots.  All the plates were then incubated at 37ºC for 24 hours-
Candida albicans, 48 hours for Aspergillus flavus (here we use the 7 days culture of Aspergillus 
flavus for excellent growth) and results were recorded. 
PROCEDURE FOR ANTIMICROBIAL ACTIVITY STUDIES: 
 The antimicrobial activity study has been done by 2 methods  
1. Minimum Inhibitory Concentration (MIC)  - Agar dilution method 
2. Zone of Inhibiton by – Agar  diffusion method 
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MINIMUM INHIBITORY CONCENTRATION BY AGAR DILUTION METHOD: 
1. The prepared and sterilized medium (15ml for bacterial strain and 5ml for fungal strains) was 
poured in sterilized petri dishes along with different compound of various dilutions (5-nitro -
2-thiophene carboxaldehyde, ciprofloxacin, gentamycin, amikacin) and allowed them to 
solidify on a plane table. 
2. Mark the plate with marker for differentiates various organisms in same plate and then a 
loopful of different bacterial cultures was inoculated at the corresponding labeled spots. 
For bacterial strains: 
1. Staphylococcus aureus 
2. Enterococcus 
3. Escherichia coli 
4. Pseudomonas aureginosa 
5. Salmonalla typhi 
      For fungal strains: 
 Candida albicans 
 Aspergillus flavus 
3. The strains inoculated all the plates were incubated at 37ºC for 24 hours all the microbes 
except Aspergillus flavus because which is incubated for 48 hours at 37ºC. 
4. Finally, after the corresponding time is over, the report is recorded. 
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ZONE OF INHIBITION FOR VARIOUS BACTERIAL STRAINS BY USING AGAR 
DIFFUSION METHOD: 
1. All of the compound (5-nitro -2-thiophene carboxaldehyde, ciprofloxacin, gentamycin, 
amikacin) were dissolved in corresponding solvent and diluted with water for proper 
concentration. 
2. All the compound were taken at the various concentrations (8µg/ml, 16µg/ml, 32µg/ml, 
64µg/ml) testing antibacterial activity.  The compound diffused into the medium produced a 
concentration gradient.  After the incubation period, the diameter of the zone was measured in 
millimeter. 
3. Following common standard strains were used for screening of antibacterial activity 
1. Staphylococcus aureus 
2. Enterococcus 
3. Escherichia coli 
4. Pseudomonas aureginosa 
5. Salmonalla typhi 
4. The plates were inoculated by dipping a sterile swab into into inoculums.  Excess inaculum 
was removed by pressing and rotating the swab firmly against the side of the tube, above the 
level of the liquid. 
5. The swab was streaked all over the surface of the medium three times, rotating the plate 
through an angle of 60ºC after each application.  Finally the swab was passed round the edge 
of the agar surface.  The inoculation was dried for a few minutes, at room temperature, with 
the lid closed. 
6. Ditch the bore in agar plate.  Add compounds solution in bore. 
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7. The plates were placed in an incubator at 37 ºC within 30 minutes of preparation of bacteria. 
8. After 24 hours incubation, the diameter of zone was measured and recorded in millimeter.  
The measurements were taken with a ruler, from the bottom of the plate without opening the 
lid. 
ANTITUBERCULAR METHOD: 
 Minimum inhibitory concentration of the Mycobacterium tuberculosis bacterium (H37Rv) is 
done by Microplate Alamar Blue Assay method (MABA). 
SPECIMEN COLLECTION: (66) 
 A good sputum specimen consists of recently discharged material from the bronchial tree, 
with minimum amounts of oral or nasal material.  Satisfactory quality implies the presence of mucoid 
or mucopurulent material and is of greater significance than volume.  Ideally, a sputum specimen 
should have a volume of approximately 5ml, although smaller quantities are acceptable if the quality 
is satisfactory which is collected from NGH institute of Dental science and Research Institute. 
 Specimens should be transported to the laboratory as soon as possible after collection.  If 
delay is unavoidable, the specimens should be refrigerated to inhibit the growth of unwanted micro-
organisms.  If refrigeration is not possible and a delay of more than 2 days is anticipated, a suitable 
preservative i.e. an equal volume of a mixture of 1% Cetyl Pyridinium Choloride (CPC) in 2% 
sodium chloride solution is recommended. 
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BIOCHMEMICAL REACTIONS(67) 
 Several biochemical tests have been described for the identification of mycobacterial species. 
i. Niacin test: 
If niacin has been extracted from the culture, a yellow color will appear in the extract within a 
few minutes. 
ii. Arylsulphatase test: 
A pink colour indicates a positive reaction. 
iii. Neutral red test: 
This test detects the ability of a strain to bind neutral red in an alkaline buffer solution.  
Positive tests are obtained with M.tuberculosis, M.bovis, M.avium, M.ulcerans. 
iv. Catalase peroxidase test: 
Effervesence indicates catalase production and browning indicates peroxidise activity. 
v. Amidase test: 
A blue colour indicates a positive test. 
vi. Nitrate reduction test: 
Positive reaction indicates the development of pink or red colour within 30-60 seconds.  This test is 
positive in M.tuberculosis and negative in M.bovis, M.aviuum 
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CPC containing specimen should be processed as described below: 
To the specimen with CPC add 15-20 ml of sterile distilled water (to reduce viscosity) 
Tighten cap of the container and mix well by inversion 
Centrifuge at 3000g for 15 minutes 
Carefully pour off the supernatant 
Add approximately 20ml of sterile distilled water to re-suspend the sediment and fill up with             
sterile distilled water to the brim 
Centrifuge again at 3000g for 15 minutes 
Decant the supernatant and inoculate deposit on two slopes of LJ medium 
Incubate all the LJ media slopes at 37ºC 
Check for growth weekly for 8 weeks 
MEDIUM: 
 Lowenstein-Jensen medium – for maintenance of Mycobacterium tuberculosis culture. 
 7H9 Broth - for growth of Mycobacterium tuberculosis bacterium. 
PREPARATION OF LOWENSTEIN-JENSEN MEDIUM: 
 Lowenstein-Jensen (LJ) medium is most widely used for tuberculosis culture.  LJ medium 
containing glycerol favours the growth of Mycobacterium tuberculosis, while LJ medium without 
glycerol but containing pyruvate encourages the growth of Mycobacteria bovis. 
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Ingredients(68) 
Mineral salt solution with malachite green 
 Pottasium dihdrogen phosphate anhydrous (KH2PO4)   2.4gm 
 Magnesium sulphate anhydrous      0.24gm 
 Magnesium citrate        0.6gm 
 Asparagine        3.6gm  
 Glycerol (reagent grade)        12ml 
 Malachite green, 2% solution       20ml 
 Malachite green solution 2% 
 Malachite green dye        2.0g 
 Distilled water        100ml 
 Dissolve the dye in distilled water completely.  Filter and store in refrigerator.  Dissolve the 
ingredients in order in about 300ml distilled water by heating.  Add glycerol, malachite green solution 
and make up 600ml with distilled water.  This solution should be sterilized by autoclaving at 121ºC 
(15 psi) for 30 minutes.  Cool to room temperature if required, otherwise stored in the refrigerator. 
Homogenized whole egg: 
 Fresh country hen’s eggs those are not more than seven days old, are cleaned by scrubbing 
thoroughly with a hand brush in water and slope.  Let the eggs soak for 30 minutes in soap solution.  
Rinse eggs thoroughly in running water and soak them in 70% ethanol for 15 minutes.  Before 
handling the clean dry eggs scrub and wash the hands with a disinfectant.  Crack the eggs with the 
edge of the beaker into a sterile flask and beat them in sterile blender for 30 seconds to one minute.  
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The following ingredients are aseptically pooled in a large, sterile flask and mixed well: 
a. Mineral salt solution with malachite green    600ml 
b. Homogenized eggs (25-30 eggs, depending on size)   1000ml 
 After mixing place the bottle in a slanted position in a inspissator and coagulate the medium 
for 50 minutes at 85ºC and whole media battle should be incubated at 35-37 ºC for 24 hours to check 
the sterility. 
INOCULATION AND INCUBATION PROCEDURES: 
INOCULATION PROCEDURES: 
 Two slopes per specimen are inoculated each with one 5 mm loopful of the centrifuged 
sediment, distributed over the surface. 100 µl of 0.5 x 106/ml of the Mycobacterium tuberculosis 
(H37Rv) were cultured in 7H9 medium in the presence of compound.  Bottle caps should be 
tightened to minimize evaporation and drying of media.  Care should be taken to avoid using red hot 
loop and loop should be cooled before inoculation. 
INCUBATION PROCEDURE: 
 All cultures should be incubated at 35-37ºC until growth is observed or discarded as negative 
after eight weeks.  Contaminated slopes are also discarded. 
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Middlebrook 7H9 Broth Base: 
 Middlebrook 7H9 Broth Base with added enrichment is recommended for cultivation and 
sensitivity testing of Mycobacterium tuberculosis. 
Composition: 
Ingredients      gm/liter 
Ammonium sulphate      0.500 
Disodium phosphate      2.500 
Mono potassium phosphate      1.000 
Sodium citrate      0.100 
Magnesium sulphate      0.050 
Calcium chloride      0.0005 
Zinc sulphate      0.001 
Copper sulphate      0.001 
Ferric ammonium citrate      0.040 
L-Glutamic acid      0.500 
Pyridoxine      0.001 
Biotin       0.0005 
Final pH (at 25ºC)      6.6±0.2 
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Directions: 
 Suspend 2.35 grams in 450 ml distilled water.  Add either 2ml glycerol or 0.5 gm polysorbate 
80.  Heat if necessary to dissolve the medium completely.  Sterilize by autoclaving at 15 lbs pressure 
(121ºC) for 10 minutes.  Cool to 45 ºC or below and aseptically add contents of 1 vial Middlebrook 
ADC Growth Supplement (FD019).  
PROCEDURE:  
a. 200 µl of sterile deionized water was added to all outer perimeter wells of sterile 96 wells 
plate to minimized evaporation of medium in the test wells during incubation. 
b. The 96 wells plate received 100 µl of the Middlebrook 7H9 broth and serial dilution of 5-
Nitro 2-Thiophene carboxaldehyde and standard drug pyrazinamide were made directly on 
plate and control plate is made with 7H9 broth and bacterium only. 
c. The final drug concentrations tested were 100 to 0.8 µg/ml.  Plates were covered and sealed 
with parafilm and incubated at 37ºC for five days. 
d. After this time, 25 µl of freshly prepared 1:1 mixture of Alamar Blue reagent and 10% Tween 
80 was added to the plate and incubated for 24 hrs. 
e. A blue color in the well was interpreted as no bacterial growth, and pink colour was scored as 
growth. 
f. The MIC was defined as lowest drug concentration which prevented the color change from 
blue to pink. 
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RESULTS 
  Emergence of new infectious diseases such as tuberculosis, bacterial and fungal 
diseases have stimulated public interest and inspired commitments to control these diseases.  
Increasing microbial resistance has become a very serious clinical problem for many classes of 
antibiotics.  Therefore, it is an urgent requirement for novel antimicrobial agents to solve the problem 
of microbial resistance towards conventional antimicrobial agents.  Among the various types of 
heterocyclic compounds, thiophene derivative possesses antibacterial, antifungal and antitubercular 
activities.  
 MINIMUM INHIBITORY CONCENTRATION FOR BACTERIAL STRAINS: 
5-NITRO-2-THIOPHENE CARBOXALDEHYDE: Table – IV: 
 
Drug 
dilution in 
mcg/ml 
ORGANISM 
GRAM POSITIVE GRAM NEGATIVE 
Staphylococcus 
aureus 
Enterococcus  E-coli Pseudomonas 
aeruginosa 
Salmonalla 
typhi 
 
1 µg/ml 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
2 µg/ml 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
3 µg/ml 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
4 µg/ml 
 
- 
 
+ 
 
+ 
 
+ 
 
+ 
 
5 µg/ml 
 
- 
 
+ 
 
+ 
 
+ 
 
+ 
 
6 µg/ml 
 
- 
 
- 
 
+ 
 
+ 
 
+ 
 
7 µg/ml 
 
- 
 
- 
 
- 
 
+ 
 
- 
 
8 µg/ml 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 (+)   Bacterial growth 
 (-)  Inhibition of bacterial growth 
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 Figure – 3  
 
    
 
  A = 1 µg/ml              B = 2 µg/ml 
     
      
 
   C = 3 µg/ml              D = 4 µg/ml 
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Figure – 4: 
 
 
 
 
  E = 5 µg/ml       F = 6 µg/ml 
 
 
 
 
  G = 7 µg/ml       H = 8 µg/ml 
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Table – V: 
CIPROFLOXACIN:  
 
 
Drug 
dilution in 
mcg/ml 
 
ORGANISM 
 
GRAM POSITIVE 
 
GRAM NEGATIVE 
Staphylococcus 
aureus 
Enterococcus E-coli Pseudomonas 
aeruginosa 
Salmonalla 
typhi 
 
 
1 µg/ml 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
           + 
 
 
2 µg/ml 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
4 µg/ml 
 
 
- 
 
 
+ 
 
 
- 
 
 
+ 
 
 
- 
 
 
8 µg/ml 
 
 
- 
 
 
+ 
 
 
- 
 
 
- 
 
 
- 
 
 
16 µg/ml 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 (+)   Bacterial growth 
 (-)  Inhibition of bacterial growth 
 
                                                                         Results                             
 
Institute of Pharmacology, MMC Page 58 
 
Figure -5 
  
         A = 1 µg/ml      B = 2 µg/ml 
          
             C = 4 µg/ml 
                
          D = 8 µg/ml           E = 16 µg/ml 
 CIP  Ciprofloxacin 
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Table - VI 
GENTAMYCIN: 
 
 
Drug 
dilution in 
mcg/m 
 
ORGANISM 
 
GRAM POSITIVE 
 
GRAM NEGATIVE 
Staphylococcus 
aureus 
Enterococcus E-coli Pseudomonas 
aeruginosa 
Salmonalla 
typhi 
 
 
1 µg/ml 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
2 µg/ml 
 
 
- 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
- 
 
 
4 µg/ml 
 
 
- 
 
 
+ 
 
 
+ 
 
 
- 
 
 
- 
 
 
8 µg/ml 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
16 µg/ml 
 
 
- 
 
 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
32 µg/ml 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 (+)   Bacterial growth 
 (-)  Inhibition of bacterial growth 
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Figure - 6 
 
    F = 1 µg/ml G = 2 µg/ml H = 4 µg/ml 
 
    I = 8 µg/ml J = 16 µg/ml K = 32 µg/ml 
 GEN   Gentamycin 
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Table - VII 
AMIKACIN:  
 
 
 
Drug 
dilution in 
mcg/m 
 
ORGANISM 
 
GRAM POSITIVE 
 
GRAM NEGATIVE 
Staphylococcus 
aureus 
Enterococcus E-coli Pseudomonas 
aeruginosa 
Salmonalla 
typhi 
 
 
 
4 µg/ml 
 
 
 
+ 
 
 
 
+ 
 
 
 
+ 
 
 
 
+ 
 
 
 
+ 
 
 
8 µg/ml 
 
 
- 
 
 
+ 
 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
16 µg/ml 
 
 
- 
 
 
+ 
 
 
- 
 
 
- 
 
 
- 
 
 
32 µg/ml 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
64 µg/ml 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 (+)   Bacterial growth 
 (-)  Inhibition of bacterial growth 
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Figure - 7 
 
 
    L = 4 µg/ml M = 8 µg/ml N = 16 µg/ml 
 
 
    O = 32 µg/ml   P = 64 µg/ml    
    AMI  Amikacin 
                                                                         Results                             
 
Institute of Pharmacology, MMC Page 63 
 
Table - VIII 
MINIMUM INHIBITORY CONCENTRATION FOR FUNGAL STRAINS: 
5-Nitro 2-thiophene carboxaldehyde 
 
 
 
Drug dilution 
in mcg/m 
 
 
ORGANISM 
 
Candida albicans 
 
Aspergillus flavus 
 
 
1 µg/ml 
 
 
+ 
 
 
+ 
 
 
3 µg/ml 
 
 
+ 
 
 
+ 
 
 
5 µg/ml 
 
 
+ 
 
 
+ 
 
 
7 µg/ml 
 
 
+ 
 
 
+ 
 
 
9 µg/ml 
 
 
- 
 
 
+ 
 
 
10 µg/ml 
 
 
- 
 
 
- 
  
 (+)   Fungal growth 
 (-)  Inhibition of fungal growth 
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Figure – 8  Candida albicans  
              
    K = 1 µg/ml                                    L = 3 µg/ml  
    
  
                        M = 5 µg/ml      
    
                 
     N = 7 µg/ml      O = 9 µg/ml 
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Figure – 9        Aspergillus flavus 
 
    A = 1 µg/ml B = 3 µg/ml C = 5 µg/ml 
 
 
    D = 7 µg/ml E = 9 µg/ml F = 10 µg/ml 
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ZONE OF INHIBITION BY AGAR WELL DIFFUSION METHOD: 
5-NITRO 2-THIOPHENE CARBOXALDEHYDE: 
Table - IX 
 
DOSE IN 
µg/ml 
 
DRUG NAME 
ORGANISMS 
Zone of inhibition in millimeter 
Staphylococcus 
aerues 
Enterococcus E-coli Peudomonas 
aureginosa 
Salmonalla 
Typhi 
 
 
 
 
 
8 µg/ml 
 
5- nitro  
2-thiophene 
carboxaldehyde 
 
 
13 
 
 
 
14 
 
 
11 
 
 
12 
 
 
10 
 
Ciprofloxacin 
 
20 
 
18 
 
18 
 
22 
 
12 
 
Gentamycin 
 
15 
 
16 
 
10 
 
11 
 
 
11 
 
Amikacin 
 
14 
 
16 
 
10 
 
10 
 
10 
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Figure - 11 
     
 
   Staphylococcus aerues      Enterococcus  
     
       escherichia coli                  
   
 
 
  Pseudomonas aureginosa     Salmonalla typhi 
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 Figure - 12  
 
 
 
Test drug   5-Nitro 2-thiophene carboxaldehyde 
Cipro         Ciprofloxacin 
Genta         Gentamycin 
Amika        Amikacin 
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Table - X 
 
 
 
DOSE 
IN  
µg/ml 
 
 
DRUG NAME 
 
ORGANISMS 
                           (Diameter of the zone in millimeter) 
Staphylococcus 
aerues 
Enterococcus E.coli Peudomonas 
aureginosa 
Salmonalla 
Typhi 
 
 
 
 
 
 
 
16 µg/ml 
 
5- nitro  
2-thiophene 
carboxaldehyde 
 
 
20 
 
 
18 
 
 
18 
 
 
 
30 
 
 
17 
 
Ciprofloxacin 
 
22 
 
21 
 
 
20 
 
28 
 
25 
 
Gentamycin 
 
18 
 
          16 
 
15 
 
15 
 
16 
 
Amikacin 
 
19 
 
17 
 
16 
 
15 
 
17 
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Figure - 13 
 
 Staphylococcus aureus  Enterococcus 
    
      Escherichia coli 
       
    
    
  Pseudomonas aureginosa       Salmonalla typhi 
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   Figure -14 
 
 
 
Test drug   5-Nitro 2-thiophene carboxaldehyde 
Cipro         Ciprofloxacin 
Genta         Gentamycin 
Amika        Amikacin 
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Table - XI 
 
 
DOSE 
IN  
µg/ml 
 
 
DRUG NAME 
ORGANISMS 
                       Diameter of the zone in millimeter 
Staphylococcus 
aerues 
Enterococcus E-coli Peudomonas 
aureginosa 
Salmonalla 
typhi 
 
 
 
 
 
32 µg/ml 
 
5- nitro 
 2-thiophene 
carboxaldehyde 
 
 
24 
 
 
19 
 
 
19 
 
 
38 
 
 
30 
 
Ciprofloxacin 
 
23 
 
22 
 
21 
 
32 
 
26 
 
Gentamycin 
 
20 
 
16 
 
16 
 
20 
 
16 
 
Amikacin 
 
20 
 
 
17 
 
20 
 
28 
 
17 
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Figure - 15 
    
  
  Staphylococcus aureus          Enterococcus 
            
       Escherichia coli 
     
  Pseudomonas aureginosa       Salmonalla typhi 
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Figure – 16 
 
 
 
 
Test drug   5-Nitro 2-thiophene carboxaldehyde 
Cipro         Ciprofloxacin 
Genta         Gentamycin 
Amika        Amikacin 
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Table - XII  
 
 
DOSE 
IN  
µg/ml 
 
 
DRUG NAME 
ORGANISMS 
                         Diameter of the zone in millimeter 
Staphylococcus 
aerues 
Enterococcus E-coli Peudomonas 
aureginosa 
Salmonalla 
Typhi 
 
 
 
 
 
64 µg/ml 
 
5- nitro  
2-thiophene 
carboxaldehyde 
 
 
25 
 
 
24 
 
 
26 
 
 
 
40 
 
 
43 
 
Ciprofloxacin 
 
25 
 
25 
 
22 
 
35 
 
32 
 
Gentamycin 
 
20 
 
18 
 
 
21 
 
20 
 
20 
 
Amikacin 
 
22 
 
19 
 
25 
 
28 
 
25 
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Figure - 17 
  
     
                    Staphylococcus aureus              Enterococcus 
    
     Escherichia coli 
 
                     
 
                  Pseudomonas aureginosa       Salmonalla typhi 
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Figure - 18 
 
 
 
Test drug   5-Nitro 2-thiophene carboxaldehyde 
Cipro         Ciprofloxacin 
Genta         Gentamycin 
Amika        Amikacin 
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ANTI –TUBERCULAR ACTIVITY:- 
 
 
S.NO 
 
SAMPLE 
NAME 
 
100 
µg/ml 
 
50 
µg/ml 
 
25 
µg/ml 
 
 
 
12.5 
µg/ml 
 
6.25 
µg/ml 
 
3.12 
µg/ml 
 
1.6 
µg/ml 
 
0.8 
µg/ml 
 
1. 
 
5- Nitro 
2–thiophene 
carboxaldehyde 
 
 
 
S 
 
 
 
S 
 
 
 
R 
 
 
 
R 
 
 
 
R 
 
 
 
R 
 
 
 
R 
 
 
 
R 
 
 S - Sensitive 
R - Resistance 
Strain used:   Mycobacterium Tuberculosis (H37RV strain) 
Figure – 18 
 
       Minimum inhibitory concentration of 5-Nitro 2-thiophene carboxaldehyde 
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DISCUSSION 
The dissertation entitled anti antimicrobial and anti-tubercular activity on 5-Nitro 2-thiophene 
carboxaldehyde. In the present work, a synthetic drugs 5-Nitro 2-Thiophene carboxaldehyde was 
selected. 
ANTIMIICROBIAL ACTIVITY: 
FOR BACTERIAL STRAINS: 
MINIMUM INHIBITORY CONCENTRATION: 
5-Nitro 2-Thiophene Carboxaldehyde: 
 The result shows that the 5-Nitro 2-Thiophene carboxaldehyde has increased bactericidal 
activity against gram positive bacteria when compared to gram negative bacteria. 
  5-Nitro 2-Thiophene carboxaldehyde at the concentration 7mcg/ml seems to be effective 
against Staphylococcus aureus, Enterococcus, E-coli and Salmonalla typhi but not against 
pseudomonas aureginosa. 
 8mcg/ml is the critical break point minimum inhibitory concentration for the 5-Nitro 2-
Thiophene carboxaldehyde compound. At this concentration all the tested pathogens were 
inhibited. 
STANDARD DRUGS: 
Ciprofloxacin: 
 Ciprofloxacin has a better Gram-negative activity than Gram-positive organisms. 
 At the concentration of 8mcg/ml, all the tested Gram-negative bacteria and Staphylococcus 
aureus were inhibited. 
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 16mcg/ml is the critical breakpoint of minimum inhibitory concentration for the 
Ciprofloxacin standard drug.  At this concentration all the test drug pathogens were 
inhibited. 
Gentamycin: 
 Gentamycin seems to have a good Gram-positive and Gram-Negative activity even at 
4mcg/ml  
 8mcg/ml is the critical breakpoint of minimum inhibitory concentration for the Gentamycin 
drug.  At this concentration all the test drug pathogens were inhibited. 
Amikacin: 
 Amikacin has the best broad spectrum activity at 16mcg/ml. 
 32mcg/ml is the critical breakpoint of minimum inhibitory concentration for the Amikacin 
drug.  At this concentration all the test drug pathogens were inhibited. 
 FOR FUNGAL STRAINS: 
 It has seems to have activity against yeast like fungi when compared to mould. 
 Candida albicans was completely inhibited at a 5-Nitro 2-Thiophene carboxaldehyde 
concentration of 9mcg/ml.  While as Aspergillus flavus was moderately inhibited. 
 10mcg/ml is the critical breakpoint of minimum inhibitory concentration for the 5-Nitro 2-
Thiophene carboxaldehyde compound.  At this concentration both yeast like fungi and moulds 
were completely inhibited. 
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ZONE OF INHIBITION: 
  Preliminary antibacterial activity was carried out for 5-Nitro 2-Thiophene 
carboxaldehyde compound using Agar well diffusion method against Staphylococcus aureus, 
Enterococcus, E.coli, Pseudomonas aeruginosa, Salmonalla typhi bacterial strains and by using the 
standard drugs like Ciprofloxacin, Gentamycin, Amikacin.  The compound shows good 
antibacterial activity on Agar diffusion method by measuring the diameter of the zone.  The 5-Nitro 
2-Thiophene carboxaldehyde compound shows antibacterial activity at concentration dependent 
manner.  The diameter of zone of inhibition was more in Pseudomonas aureginosa and Salmonalla 
typhi at all increasing concentrations (8 µg/ml, 16 µg/ml, 32 µg/ml, 64 µg/ml) than other organisms 
like Staphylococcus aureus, Enterococcus and E-coli.  Order of organisms based on the diameter of 
the zones: Pseudomonas aureginosa > Salmonalla typhi > Staphylococcus aureus > Enterococcus > 
E-Coli. 
  When compared to the standard drugs like Ciprofloxacin, Gentamycin, amikacin, the 
inhibitory zone diameter at all increasing concentration is relatively equal to that of the 
ciprofloxacin. So this drug having significant antibacterial activity. 
  The 5-Nitro 2-Thiophene carboxaldehyde showed best antimicrobial activity at very 
low concentration at 8µg/ml.  Its potency was greater while comparing to the standard drugs. 
  Under the standard laboratory conditions, it has been found that 5-Nitro 2-thiophene 
carboxaldehyde at a concentration of 8µg/ml seems to be highly effective against staphylococcus 
aureus, Enterococcus, E-Coli, Pseudomonas aureginosa and Salmonalla typhi, when tested at a 
condition of 1.5x108 CFU (Colony forming unit/ml).  But under the practical condition 5-Nitro 2-
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thiophene carboxaldehyde would be highly effective against most of the commonly isolated 
pathogens. 
ANTI-TUBERCULAR ACTIVITY: 
  Invitro anti-tubercular potency of 5-Nitro 2-Thiophene carboxaldehyde compound was 
determined by Microplate Alamar Blue Assay (MABA) method. Inhibition of growth of 
Mycobacterium tuberculosis H37Rv cell lines by MABA method, the compound containing wells 
after 24 hours of incubation at 37ºC were recorded from the concentration of 100µg/ml to 0.8µg/ml. 
This compound shows Minimum Inhibitory Concentration (MIC) at 50µg/ml by preventing the 
colour change from blue to Pink.  Change in the colour from blue to pink was scored as growth.  So 
this compound shows the antitubercular activity.  
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CONCLUSION 
  Multiple drug resistance has developed due to the indiscriminate use of commercial 
antimicrobial drugs commonly used in the treatment of infectious diseases.  In addition to this 
problem, antibiotics are sometimes associated with adverse effect on the host including 
hypersensitivity, immune supervision and allergic reaction.  This situation forced scientist to search 
for new antimicrobial substances to search for new antimicrobial substances.  Given the alarming 
incidence of antibiotic resistances in bacteria of medical importance, there is a constant need for new 
and effective therapeutic agents. 
 
 5-Nitro 2-Thiophene carboxaldehyde compound shows best antibacterial activity. 
 5-Nitro 2-Thiophene carboxaldehyde compound shows best antifungal activity. 
 5-Nitro 2-Thiophene carboxaldehyde compound has anti-tubercular activity. 
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